Dysentery medical therapy

Dysentery Microchapters
Home
Patient Information
Overview
Pathophysiology
Causes
Differentiating Dysentery from other Diseases
Epidemiology and Demographics
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
Treatment
Medical Therapy
Primary Prevention
Secondary Prevention
Case Studies
Case #1
Dysentery medical therapy On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
slides
Images
American Roentgen Ray Society Images of Dysentery medical therapy All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Dysentery medical therapy
on Dysentery medical therapy
Dysentery medical therapy in the news
Blogs on Dysentery medical therapy
Directions to Hospitals Treating Dysentery
Risk calculators and risk factors for Dysentery medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Kalsang Dolma, M.B.B.S.[2]

Medical Therapy

Dysentery is initially managed by maintaining fluid intake using oral rehydration therapy. If this treatment cannot be adequately maintained due to vomiting or the profuseness of diarrhea, hospital admission may be required for intravenous fluid replacement. In ideal situations, no antimicrobial therapy should be administered until microbiological microscopy and culture studies have established the specific infection involved. When laboratory services are not available, it may be necessary to administer a combination of drugs, including an amoebicidal drug to kill the parasite and an antibiotic to treat any associated bacterial infection.

If shigella is suspected and it is not too severe, the doctor may recommend letting it run its course — usually less than a week. The patient will be advised to replace fluids lost from diarrhea. If the shigella is severe, the doctor may prescribe antibiotics, such as ciprofloxacin or TMP-SMX (Bactrim). However, many strains of shigella are becoming resistant to common antibiotics, and effective medications are often in short supply in developing countries. If necessary, a doctor may have to reserve antibiotics for those at highest risk for death, including young children, people over 50, and anyone suffering from dehydration or malnutrition.

Amoebic dysentery usually calls for a two-pronged attack. Treatment should start with a 10-day course of the antimicrobial drug metronidazole (Flagyl). To finish off the parasite, the doctor can prescribe a course of diloxanide furoate (available only through the Centers for Disease Control and Prevention), paromomycin (Humatin), or iodoquinol (Yodoxin).

Shown below is a table summarizing the preferred and alternative empiric treatment for Dysentery.

Possible Pathogens	Characteristics of the Patient	Preferred Treatment	Duration of Treatment
Shigella species	Immunocompetent patient	TMP-SMZ, 160 and 800 mg, respectively (pediatric dose, 5 and 25 mg/kg, respectively) b.i.d. (if susceptible) OR Fuoroquinolone (e.g., 300 mg ofloxacin, 400 mg norfloxacin, or 500 mg ciprofloxacin b.i.d.); nalidixic acid, 55 mg/kg/d (pediatric) or 1 g/d (adults) OR Ceftriaxone OR Azithromycin	TMP-SMZ for 3 days OR Flouroquinolones [( ofloxacin,norfloxacin and ciprofloxacin for 3 days ) and (nalidixic acid for 5 days )]
Shigella species	Immunocompromised patient	Same as above	Same as above except that duration of antibiotics is for 7- 10 days
Non-typhi species of Salmonella	Immunocompetent patient Not recommended routinely, but if Severe or patient is <6 mo or >50 y old Prostheses Valvular heart disease Severe atherosclerosis Malignancy Uremia,	TMP-SMZ (if susceptible) or fluoroquinoloneas above, b.i.d; OR Ceftriaxone, 100 mg/kg/d in 1 or 2 divided doses	TMP-SMZ (if susceptible) or fluoroquinolone for 5 - 7 days
Non-typhi species of Salmonella	Immunocompromised patient	Same as above	Same as above except that duration of antibiotics is for 14 days (or longer if relapsing)
Campylobacter species	Immunocompetent patient	Erythromycin 500 mg b.i.d.	Erythromycin for 5 days
Campylobacter species	Immunocompromised patient	Same as above	Same as above but may require prolonged treatment
Enterohemorrhagic E Coli	Immunocompetent patient Immunocompromised patient	Avoid antimotility drugs ; role of antibiotics unclear,and administration should be avoided	Avoid antimotility drugs ; role of antibiotics unclear,and administration should be avoided
Yersina species	Immunocompromised patient Bacteremia Pseudoappendicitis syndrome	TMP-SMZ, 160 and 800 mg, respectively (pediatric dose, 5 and 25 mg/kg, respectively) b.i.d. (if susceptible) OR ciprofloxacin 500 mg b.i.d. OR Doxycycline 100 mg PO b.i.d.	TMP-SMZ for 3 - 5 days OR Ciprofloxacin for 3 days OR Doxycycline for 3 days
Entamoeba histolytica	Immunocompetent patient Immunocompromised patient	Metronidazole, 750 mg t.i.d. + Diiodohydroxyquin, 650 mg t.i.d. OR Paromomycin, 500 mg t.i.d.	Metronidazole for 5 - 10 days + Diiodohydroxyquin for 20 days OR Paromomycin for 7 days